Savings from Biosimilars since 2015 #GRxBiosimsSavingsReport @accessiblemeds
Savings from Biosimilars since 2015 #GRxBiosimsSavingsReport  @accessiblemeds
Uploaded November 2022 | Updated November 2026, 3 hours ago
Since the first biosimilar approval in 2015, biosimilars have saved $13.3 billion for our health care system and patients. Biosimilars were used in more than 364 million days of patient therapy. Importantly, biosimilars led to more than 150 million incremental days of therapy.

Learn more in AAM's 2022 #GRxBiosimsSavingsReport: bit.ly/3UnZc7G
Savings from Biosimilars since 2015 #GRxBiosimsSavingsReportBriefing: How NAFTA/Trade Policy Proposals Undermine Trump Administration Drug Pricing BlueprintAAM Lifetime Achievement Award - Joe RennerJoin us a GRx+Biosims 2021 — Progress + ProcessAAM Lifetime Achievement Award at Access! 2022GRx+Biosims 2022Christine Simmon: Policy and Biosimilars Sessions at the GRx+Biosims 2020 Virtual ConferencePatient Perspective on the Value of Biosimilars During IGBA #GlobalBiosimilarsWeekGeneric Drugs Are the Prescription for Savings. Dont Take Them for Granted.The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMedsMessage from CEO Dan Leonard on Access! 2021AAM All Access Promo: Mary Beth Powers
Association for Accessible Medicines |

Savings from Biosimilars since 2015 #GRxBiosimsSavingsReport

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER